Last reviewed · How we verify

NCT06161727

Detection and Prevalence of Human Papillomavirus (HPV) in Seminal Plasma and/or on Sperm in Men Undergoing Treatment With IVF/ICSI.

Completed Last updated 26 April 2024
What this trial tests

trial testing HPV exposure in Human Papilloma Virus in 260 participants. Completed in 28 March 2024.

Timeline
1 January 2023
Primary endpoint
30 January 2024
28 March 2024

Quick facts

Lead sponsorVastra Gotaland Region
StatusCompleted
Study typeOBSERVATIONAL
Enrollment260
Start date1 January 2023
Primary completion30 January 2024
Estimated completion28 March 2024
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

Adults 18 to 60, male only, with Human Papilloma Virus or Infertility, Male. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to investigate the presence of HPV DNA in semen samples from men undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment. It focuses on understanding the impact of HPV on male fertility and embryo development following IVF/ICSI. The primary goal is to determine the prevalence of HPV-positive (HPV+) semen samples among men seeking infertility treatment with IVF/ICSI. Additionally, the study aims to compare semen characteristics between HPV-positive and HPV-negative (HPV-) samples and assess the embryological outcomes after IVF/ICSI in these two groups. Participants in this study will include men receiving IVF/ICSI treatment and providing fresh ejaculated sperm at Sahlgrenska University Hospital in Gothenburg, Sweden, over one year. Those undergoing treatments with surgically extracted sperm, sperm freezing for fertility preservation, or planning treatments involving preimplantation genetic testing or egg donation will be excluded. The study will involve analyzing HPV DNA in semen samples through PCR, utilizing the most effective method for HPV DNA detection previously identified in a pilot study. Sperm samples collected during infertility investigations and IVF/ICSI treatments will undergo gradient centrifugation to separate different components. A portion of the sperm sample will be preserved for PCR analysis to detect HPV DNA, while the rest will be used for IVF/ICSI procedures. The results from the PCR analyses will be correlated with semen characteristics and the outcomes of IVF/ICSI treatment. Furthermore, the samples will be stored for potential future analyses related to HPV-related biomarkers for up to 5 years at Biobank.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Semen HPV and IVF: insights from infection prevalence to embryologic outcomes.
    Francis J, Tsiartas P, Hreinsson J, Andersson M, et al · · 2025 · PMID 40402400 · DOI 10.1007/s10815-025-03513-6

Verify or expand the search:

Other recruiting trials for Human Papilloma Virus

Currently open trials in the same condition.

Other Vastra Gotaland Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing